Caribou Biosciences to Participate in Upcoming Investor Conferences
Globe Newswire (Thu, 12-Feb 4:05 PM ET)
Globe Newswire (Wed, 4-Feb 8:00 AM ET)
Precision's Payoff: Targeted Therapies Drive $131B Solid Tumor Market Surge
Globe Newswire (Wed, 24-Dec 6:00 AM ET)
Caribou Biosciences to Host In-Person and Virtual KOL Event at ASH 2025
Globe Newswire (Mon, 1-Dec 4:05 PM ET)
Market Chameleon (Mon, 3-Nov 4:54 AM ET)
Market Chameleon (Mon, 3-Nov 2:05 AM ET)
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. The company operates and manage business as one reportable operating segment, which is the business of developing a pipeline of allogeneic CAR-T and CAR-NK cell therapies. Geographically, it operates in United States and Rest of the World, of which United States derives maximum revenue.
Caribou Biosciences trades on the NASDAQ stock market under the symbol CRBU.
As of February 13, 2026, CRBU stock price climbed to $1.61 with 457,452 million shares trading.
CRBU has a beta of 2.20, meaning it tends to be more sensitive to market movements. CRBU has a correlation of 0.21 to the broad based SPY ETF.
CRBU has a market cap of $150.48 million. This is considered a Micro Cap stock.
Last quarter Caribou Biosciences reported $2 million in Revenue and -$.30 earnings per share. This beat revenue expectation by $55,680 and exceeded earnings estimates by $.06.
In the last 3 years, CRBU traded as high as $8.59 and as low as $.66.
The top ETF exchange traded funds that CRBU belongs to (by Net Assets): VTI, VXF, IBB, SCHA, NXTE.
CRBU has outperformed the market in the last year with a price return of +24.8% while the SPY ETF gained +14.5%. However, in the short term, CRBU had mixed performance relative to the market. It has underperformed in the last 3 months, returning -28.8% vs +0.4% return in SPY. But in the last 2 weeks, CRBU shares have fared better than the market returning +8.8% compared to SPY -1.5%.
CRBU support price is $1.44 and resistance is $1.60 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CRBU shares will trade within this expected range on the day.